Lv1
2 积分 2023-12-06 加入
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2个月前
已完结
Oral Muvalaplin for Lowering of Lipoprotein(a)
2个月前
已完结
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
2个月前
已完结
Lipoprotein(a)
2个月前
已完结
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
2个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
3个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
3个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
3个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
3个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
4个月前
已完结
皖公网安备34019202002308
